Investment Analysts’ Weekly Ratings Changes for Viridian Therapeutics (VRDN)

Several brokerages have updated their recommendations and price targets on shares of Viridian Therapeutics (NASDAQ: VRDN) in the last few weeks:

• 6/30/2026 – Viridian Therapeutics had its price target raised by Truist Financial Corporation from $35.00 to $38.00. They now have a “buy” rating on the stock.
• 6/30/2026 – Viridian Therapeutics had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $39.00 price target on the stock.
• 6/30/2026 – Viridian Therapeutics had its price target raised by Royal Bank Of Canada from $34.00 to $35.00. They now have an “outperform” rating on the stock.
• 6/30/2026 – Viridian Therapeutics had its price target raised by Wedbush from $32.00 to $43.00. They now have an “outperform” rating on the stock.
• 6/29/2026 – Viridian Therapeutics was upgraded by Wells Fargo & Company from “equal weight” to “overweight”. They now have a $31.00 price target on the stock, up from $20.00.
• 6/29/2026 – Viridian Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $32.00 price target on the stock.
• 6/14/2026 – Viridian Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/15/2026 – Viridian Therapeutics was given a new $26.00 price target by Evercore Inc.
• 5/13/2026 – Viridian Therapeutics was given a new $39.00 price target by Stifel Nicolaus.
• 5/9/2026 – Viridian Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/6/2026 – Viridian Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $34.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Viridian Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $32.00 price target on the stock.

Insiders Place Their Bets

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the company’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the acquisition, the director directly owned 5,090,928 shares in the company, valued at approximately $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by company insiders.

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.